U.S. markets open in 5 hours 18 minutes
  • S&P Futures

    +52.00 (+1.13%)
  • Dow Futures

    +292.00 (+0.83%)
  • Nasdaq Futures

    +257.50 (+1.63%)
  • Russell 2000 Futures

    +35.30 (+1.60%)
  • Crude Oil

    +1.70 (+2.45%)
  • Gold

    +2.60 (+0.15%)
  • Silver

    +0.15 (+0.66%)

    -0.0028 (-0.25%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    -6.83 (-22.27%)

    -0.0009 (-0.06%)

    +0.2100 (+0.19%)

    +3,243.82 (+6.76%)
  • CMC Crypto 200

    +66.29 (+5.26%)
  • FTSE 100

    +78.60 (+1.09%)
  • Nikkei 225

    +528.23 (+1.89%)

Orgenesis Announces Collaboration with The John Hopkins University for the Development and Processing of Cell and Gene Based Clinical Therapeutics

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

GERMANTOWN, Md., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (ORGS), a provider of point-of-care cell and gene therapy development, processing and treatment solutions (“POCare”), today announced that it has entered into a collaboration agreement with the John Hopkins University (“JHU”) to utilize Orgenesis’ POCare platform to develop and supply a variety of cell and gene therapies and technologies, including cell-based immunotherapy technologies.

Vered Caplan, CEO of Orgenesis, stated, “JHU has unparalleled capabilities in the cell and gene therapy sector. Our POCare platform is designed to provide unique cell and gene therapy solutions in a cost effective, high quality and scalable manner, using closed systems and other advanced cell processing technologies at the point of care. We look forward to utilizing our POCare platform to support JHU’s growing development and processing needs in order to advance and accelerate cell and gene based clinical therapeutic research. We believe this collaboration with JHU, a clear leader in the field of cell and gene therapy, further validates the significant value proposition of our POCare platform. Moreover, this is the third major agreement signed by an international institution in recent months to utilize Orgenesis’ POCare solutions.”

About Orgenesis
Orgenesis is a biopharmaceutical company specializing in the development, manufacturing and processing of technologies and services in the cell and gene therapy industry. The Company operates a point-of-care (“POCare”) cell therapy platform whose aim is to further the development of Advanced Therapy Medicinal Products (“ATMPs”) through collaborations and in-licensing with other pre-clinical and clinical-stage biopharmaceutical companies and research and healthcare institutes to bring such ATMPs to patients. The Company out-licenses these ATMPs through regional partners to whom it also provides regulatory, pre-clinical and training services to support their activity in order to reach patients in a point-of-care hospital setting. Additional information is available at: www.orgenesis.com.

Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. These forward-looking statements involve substantial uncertainties and risks and are based upon our current expectations, estimates and projections and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including, but not limited to, our reliance on, and our ability to grow, our point-of-care cell therapy platform, our ability to effectively use the net proceeds from the sale of Masthercell, our ability to achieve and maintain overall profitability, the sufficiency of working capital to realize our business plans, the development of our POCare strategy, our trans-differentiation technology as therapeutic treatment for diabetes which could, if successful, be a cure for Type 1 Diabetes, the technology behind our in-licensed ATMPs not functioning as expected, our ability to retain key employees, our competitors developing better or cheaper alternatives to our products and the risks and uncertainties discussed under the heading "RISK FACTORS" in Item 1A of our Annual Report on Form 10-K for the fiscal year ended November 30, 2018, and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.

Investor contact for Orgenesis:
Crescendo Communications, LLC
Tel: 212-671-1021

Media contact for Orgenesis:
Image Box PR
Neil Hunter / Michelle Boxall
Tel +44 (0)20 8943 4685
neil@imageboxpr.co.uk / michelle@imageboxpr.co.uk